氟昔洛韦PET/CT在伴肾上腺转移的去势抵抗性前列腺癌中的潜在陷阱
一例83岁去势抵抗性前列腺癌患者行18F-氟昔洛韦PET/CT,局部及区域淋巴结阴性,见多发氟昔洛韦高摄取骨转移,双侧肾上腺轻度摄取结节初判良性;10个月后随访PET/CT示双侧结节增大为肿块且氟昔洛韦摄取间隔性减低,疑肾上腺转移,CT引导活检证实前列腺癌转移且无肿瘤坏死。该假阴性病例凸显氟昔洛韦PET表征肾上腺病灶的诊断挑战。
要点
- 氟昔洛韦PET/CT可漏诊前列腺癌肾上腺转移,双侧轻度摄取结节不应轻判良性。
- 随访中肾上腺结节增大为肿块且摄取间隔性减低,活检证实为转移且无坏死。
- 该假阴性病例提示氟昔洛韦PET表征肾上腺病灶存在诊断挑战。
核心结论
- 该假阴性病例凸显氟昔洛韦PET在表征肾上腺病灶方面的诊断挑战。
研究设计与样本
- 个案报告:一例83岁去势抵抗性前列腺癌患者行18F-氟昔洛韦PET/CT及10个月后随访PET/CT,并行CT引导活检。
主要发现
- 首次18F-氟昔洛韦PET/CT对局部复发或区域淋巴结病变阴性,但见多发氟昔洛韦高摄取骨转移。
- 首次检查见双侧肾上腺轻度摄取结节,当时考虑为良性。
- 10个月后随访PET/CT(患者正在接受恩扎卢胺额外治疗)示双侧结节变为肿块病变,氟昔洛韦摄取间隔性减低。
- 因快速生长怀疑肾上腺转移,CT引导活检证实为前列腺癌转移且无肿瘤坏死。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An 83-year-old man with castrate-resistant prostate cancer underwent an 18 F-fluciclovine PET/CT scan, which was negative for local disease recurrence or locoregional lymphadenopathy, but there were multiple fluciclovine-avid bone metastases. In addition, mildly avid bilateral adrenal nodules were thought to be benign. However, on follow-up PET/CT 10 months later, while on additional therapy with enzalutamide, the bilateral nodules became mass lesions with interval decreased fluciclovine avidity. Adrenal metastases were suspected given their rapid growth, with subsequent CT-guided biopsy revealing metastatic prostate cancer without tumor necrosis. This false-negative case highlights the diagnostic challenge of fluciclovine PET in characterizing adrenal lesions.
引用
- Qi J, Nguyen NC. Potential Pitfall of Fluciclovine PET/CT in Castrate-Resistant Prostate Cancer With Adrenal Metastasis. Clin Nucl Med. 2022. PMID: 36026595. doi:10.1097/RLU.0000000000004373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。